BGI Increases Long-Read Sequencing Capacity with Purchase of 10 PacBio Sequel Systems
Thursday, January 25, 2018
“We have been very impressed with the SMRT Sequencing technology. The Sequel System will allow BGI to meet the growing demand for SMRT Sequencing services for bacterial, plant, and animal de novo, transcriptomics, and epigenomics sequencing, and also in fields outside of agriculture, such as in conservation biology, like the ‘Life Periodic Plan’ that we just launched during the 2018
The Sequel System provides an unmatched depth of genetic information through exceptionally long sequencing reads, uniform coverage, and the highest consensus accuracy available today. The technology allows scientists to
go beyond fragmented draft genomes and generate the most comprehensive and high-quality de novo assemblies.
“BGI has continually expanded its SMRT Sequencing capacity based on steadily rising demand from its vast user base,” said
For more information, please visit https://www.pacb.com/.
About Pacific Biosciences
sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to purchase commitments, future
availability, uses, quality or performance of, or benefits of using, products or technologies, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.”
Pacific Biosciences undertakes no obligation to revise or update information in this press
release to reflect events or circumstances in the future, even if new information becomes available.
News Provided by Acquire Media